EQS-News: International Experts Highlight Demand for Diagnostic Innovations as PenKid's Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools
Recently published scientific data affirms that penKid remains informative under acute renal replacement therapy (RRT) and can identify patients for successful liberation.
Issuer: SphingoTec GmbH / Key word(s): Research Update/Conference International Experts Highlight Demand for Diagnostic Innovations as PenKid's Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools 06.09.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement.
Hennigsdorf/Berlin, Germany, September 6, 2023 – Diagnostic company SphingoTec has announced that a new study and real-world data on its kidney function biomarker penKid underline its potential to monitor kidney function during acute kidney injury (AKI) and RRT and to support liberation decisions from RRT. These findings are especially relevant in the context of a liberation failure rate of up to 50% (1), considering the lack of consensus guidelines, and tools to support clinical decision-making.
Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |